Moderna, Inc. (MRNA) Stock: Slide as Company Upsizes Debt Offering to $2.6 Billion

TLDR

Table of Contents

Moderna upsizes its convertible notes offering to $2.6 billion as MRNA shares fall.
MRNA closes 4.60% lower as Moderna expands its convertible debt financing plan.
The notes carry a 0.00% rate and an initial conversion price of about $210.58.
Moderna expects up to $2.96 billion in net proceeds if the full option is used.
Capped call transactions aim to limit dilution tied to future note conversions.

Moderna (MRNA) shares fell after the company increased its convertible debt offering to $2.6 billion from the previously announced $2.0 billion. MRNA closed 4.60% lower at $142.77, then slipped another 0.24% to $142.43 in pre-market trading. The larger financing gives Moderna added capital flexibility while creating new dilution concerns around the convertible securities.

Moderna, Inc., MRNA

Moderna Expands Convertible Notes Offering

Moderna priced $2.6 billion of 0.00% convertible senior notes due in 2032 through a private institutional placement. The company also granted initial purchasers an option to buy another $400 million of notes during a 13-day period. Moderna expects the transaction to close on September 1, subject to standard closing conditions.

The notes will rank as senior unsecured obligations and will not carry regular interest or principal accretion. They will mature on March 1, 2032, unless holders convert them or Moderna redeems or repurchases them earlier. The structure allows Moderna to raise substantial capital without paying regular cash interest during the notes’ life.

Moderna expects net proceeds of about $2.56 billion after discounts and estimated offering expenses. That amount could rise to about $2.96 billion if purchasers fully exercise the additional $400 million option. The company plans to use proceeds for capped calls, general purposes, oncology growth, and possible debt repayment.

Conversion Terms Set Above Current MRNA Share Price

The notes initially convert at 4.7487 Moderna shares for each $1,000 of principal. That rate equals an initial conversion price of about $210.58 per share. The price stands about 47.5% above Moderna’s $142.77 closing price on August 27.

Moderna may settle conversions with cash, common shares, or a combination of both at its discretion. The conversion rate may change after specified corporate events or certain redemption notices. Those provisions could increase the shares available to qualifying noteholders under defined circumstances.

Moderna cannot redeem the notes before September 6, 2029, except under specified cleanup provisions. After that date, redemption becomes possible if Moderna shares meet the required price and trading conditions. The company can also redeem all remaining notes if outstanding principal falls below $100 million under stated terms.

Capped Calls Aim to Limit Potential Share Dilution

Moderna entered capped call transactions with financial institutions alongside the note pricing. The transactions cover the shares initially linked to the notes and aim to reduce potential dilution. They may also offset cash payments above principal when holders convert notes under qualifying conditions.

The capped call price starts at $392.6175, representing a 175% premium to Moderna’s August 27 closing price. Moderna expects to spend about $285 million of offering proceeds on these transactions. The company may arrange additional capped calls if purchasers exercise the extra-note option.

The counterparties may buy Moderna shares or use derivatives while establishing and adjusting hedge positions. Those trades can affect Moderna’s share price during the offering period and later conversion windows. Meanwhile, the Rule 144A offering remains limited to qualified institutional buyers and does not involve registered public securities.

✨ Limited Time Offer